Clinical Trials Procurement Intelligence Report, 2024 - 2030 (Revenue Forecast, Supplier Ranking & Matrix, Emerging Technologies, Pricing Models, Cost Structure, Engagement & Operating Model, Competitive Landscape)

Research Scope & Content Outline

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Research Methodology
                    1.3. Research Scope & Assumption
                    1.4. Information Procurement
                         1.4.1. Purchased Database
                         1.4.2. GVR’s Internal Database
                         1.4.3. Secondary Sources & Third-Party Perspectives
                         1.4.4. Primary Research
                    1.5. Information Analysis
                         1.5.1. Data Analysis Models
                    1.6. Market Formulation & Data Visualization
                    1.7. Data Validation & Publishing
Chapter 2. Clinical Trials Market Intelligence
                    2.1. Category Definition
                    2.2. Category Intelligence
                         2.2.1. Market Size
                         2.2.2. Trends
                         2.2.3. Drivers
                         2.2.4. Challenges
                         2.2.5. Regional/ End-use Application Insights
                    2.3. Technology
                         2.3.1. Emerging Technology
                         2.3.2. Best Practices in the Industry
                    2.4. Regulatory Landscape
                    2.5. Porter’s Five Forces Analysis
                         2.5.1. Bargaining power of suppliers
                         2.5.2. Bargaining power of buyers
                         2.5.3. Threat of substitutes
                         2.5.4. Threat of new entrants
                         2.5.5. Competitive rivalry
Chapter 3. Clinical Trials - Supplier Intelligence
                    3.1. Identification of top 10 suppliers
                         3.1.1. IQVIA Inc.
                         3.1.2. PAREXEL International Corporation
                         3.1.3. Pharmaceutical Product Development (PPD) LLC
                         3.1.4. Charles River Laboratory
                         3.1.5. ICON Plc
                         3.1.6. Syneos Health Inc.
                         3.1.7. Chiltern International Ltd (now, Covance Clinical-Biotec under Labcorp)
                         3.1.8. Eli Lilly and Company
                         3.1.9. Pfizer, Inc.
                         3.1.10. Caidya
                    3.2. Clinical Trials Supplier Landscape
                    3.3. Clinical Trials Supplier Ranking Methodology
                         3.3.1. Supplier Operational Capabilities
                              3.3.1.1. Years in Service
                              3.3.1.2. Geographical Service Provision
                              3.3.1.3. Industries Served
                              3.3.1.4. Employee Strength
                              3.3.1.5. Revenue/Sales Turnover
                              3.3.1.6. Certifications
                              3.3.1.7. Key clients
                         3.3.2. Supplier Functional Capabilities
                              3.3.2.1. Site Management
                              3.3.2.2. Data Management
                              3.3.2.3. Regulatory Compliance
                              3.3.2.4. Patient Safety
                              3.3.2.5. Communication Tools/Devices
                              3.3.2.6. Others
                    3.4. Clinical Trials - Supplier Scoring Criteria
                    3.5. Clinical Trials - Supplier Positional Matrix (SPM)
                         3.5.1. Rulers
                         3.5.2. Challengers
                         3.5.3. Loungers
                         3.5.4. Niches
                    3.6. Clinical Trials - Supplier Market Concentration
                         3.6.1. Industry structure
                    3.7. Recommended Suppliers
                         3.7.1. Supplier 1 with detailed profile
                         3.7.2. Supplier 2 with detailed profile
                         3.7.3. Supplier 3 with detailed profile
Chapter 4. Competitive Landscape
                    4.1. Recent Supplier Developments with Measured Impact
                         4.1.1. Joint Ventures
                         4.1.2. Mergers & Acquisitions
                         4.1.3. Collaborations or Partnerships
                         4.1.4. Other major developments
                    4.2. Supply - Demand Analysis
                         4.2.1. Supply Analysis
                         4.2.2. Demand Analysis
Chapter 5. Clinical Trials - Pricing and Cost Intelligence
                    5.1. Cost Structure Overview
                         5.1.1. Clinical trial consultants/experts' salaries
                         5.1.2. Patient care and research cost
                         5.1.3. Technology and equipment
                         5.1.4. R&D, compliance, and testing
                         5.1.5. Infrastructure and insurance
                         5.1.6. Others
                    5.2. Factors influencing the cost of Clinical Trials
                         5.2.1. Phase, complexity of trial design and protocol
                         5.2.2. Duration of the trial
                         5.2.3. Therapeutic area and type of disease
                         5.2.4. Associated risks
                         5.2.5. Others
                    5.3. Clinical Trials - Pricing Model Analysis
                         5.3.1. Cost plus pricing or,
                         5.3.2. Hourly rate-based pricing or,
                         5.3.3. Fixed rate pricing or,
                         5.3.4. Project-based pricing
                    5.4. Clinical Trials Service Prices - Few Examples
Chapter 6. Sourcing Intelligence
                    6.1. Engagement Model
                         6.1.1. Fully Outsourcing Model or,
                         6.1.2. Partial/Hybrid Outsourcing Model or,
                         6.1.3. In-house Product Development Model or,
                         6.1.4. Shared Service Model
                    6.2. Operating Model
                         6.2.1. Basic Provider or,
                         6.2.2. Approved Provider or,
                         6.2.3. Others
                    6.3. KPI/SLA Elements
                    6.4. Negotiation Strategies
                    6.5. LCC/BCC Sourcing Analysis
                         6.5.1. U.S.
                         6.5.2. U.K.
                         6.5.3. Germany
                         6.5.4. South Korea
                         6.5.5. China
                         6.5.6. India
                         6.5.7. Insights on Top 2 LCC/BCC Countries